CA2834829A1 - Rifaximin dimethylformamide solvate - Google Patents

Rifaximin dimethylformamide solvate Download PDF

Info

Publication number
CA2834829A1
CA2834829A1 CA2834829A CA2834829A CA2834829A1 CA 2834829 A1 CA2834829 A1 CA 2834829A1 CA 2834829 A CA2834829 A CA 2834829A CA 2834829 A CA2834829 A CA 2834829A CA 2834829 A1 CA2834829 A1 CA 2834829A1
Authority
CA
Canada
Prior art keywords
rifaximin
solvate
hours
dimethylformamide
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2834829A
Other languages
English (en)
French (fr)
Inventor
Jagdev Singh Jaryal
Munish Kapoor
Swargam Sathyanarayana
Rajesh Kumar Thaper
Mohan Prasad
Sudershan Kumar Arora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of CA2834829A1 publication Critical patent/CA2834829A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2834829A 2011-05-02 2012-05-02 Rifaximin dimethylformamide solvate Abandoned CA2834829A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1289DE2011 2011-05-02
IN1289/DEL/2011 2011-05-02
PCT/IB2012/052200 WO2012150561A1 (en) 2011-05-02 2012-05-02 Rifaximin dimethylformamide solvate

Publications (1)

Publication Number Publication Date
CA2834829A1 true CA2834829A1 (en) 2012-11-08

Family

ID=46124584

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2834829A Abandoned CA2834829A1 (en) 2011-05-02 2012-05-02 Rifaximin dimethylformamide solvate

Country Status (4)

Country Link
EP (1) EP2705042A1 (de)
AU (1) AU2012251385A1 (de)
CA (1) CA2834829A1 (de)
WO (1) WO2012150561A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1698630T3 (pl) 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014167533A1 (en) 2013-04-12 2014-10-16 Alfa Wassermann S.P.A. Nsaid administration and related compositions, methods and systems.
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
AU2015260837B2 (en) * 2014-05-12 2019-02-28 Alfasigma S.P.A. New solvated crystal form of rifaximin, production, compositions and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
PL1698630T3 (pl) 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
AU2007298733B2 (en) 2006-09-22 2012-11-08 Cipla Limited Rifaximin
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8067429B2 (en) * 2008-02-25 2011-11-29 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
SG185490A1 (en) * 2010-06-03 2012-12-28 Salix Pharmaceuticals Ltd New forms of rifaximin and uses thereof

Also Published As

Publication number Publication date
WO2012150561A1 (en) 2012-11-08
EP2705042A1 (de) 2014-03-12
AU2012251385A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
CA2834829A1 (en) Rifaximin dimethylformamide solvate
JP7346353B2 (ja) リファキシミン
US8883795B2 (en) Polymorphic forms of Rifaximin
CA2793413C (en) Crystal form of edoxaban tosylate monohydrate and method of producing same
JP2011057698A (ja) リファキシミンの多形体、それらの製造方法および医薬製剤におけるそれらの使用
EP3664805A1 (de) Polymorphe und co-kristalle von roxadustat
EP4180435A1 (de) Kristallform von upadacitinib, herstellungsverfahren dafür und verwendung davon
WO2010070677A2 (en) A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof
CN111777595A (zh) 一种环己烷甲酰胺类化合物的新晶型及其制备方法
WO2013027227A1 (en) Novel polymorphic form i of rifaximin
WO2009151770A2 (en) Colchicine solid-state forms; methods of making; and methods of use thereof
US7745429B2 (en) Crystal forms of olanzapine and processes for their preparation
JP2016533361A (ja) ピラゾロピリジン化合物の固体形態
CA2596754C (en) Crystalline 1h-imidazo[4,5-b]pyridin-5-amine,7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its uses for the treatment of inflammatory, autoimmune and proliferative diseases and disorders
EP3473623B1 (de) Kristalline formen von nbi-98854, herstellungsverfahren dafür und verwendung davon
CN113045554A (zh) 一种非索替尼晶型及其制备方法
WO2020053660A1 (en) Solid forms of a bet inhibitor
Suzuki et al. Studies on mechanism of thermal crystal transformation of sitafloxacin hydrates through melting and recrystallization, yielding different anhydrates depending on initial crystalline forms
CN115413277B (zh) 吡嗪取代的烟酰胺的固体形式及其制备和用途
EP3327007A1 (de) Orbitazinfumarat-, hydrat-, kristallform und herstellungsverfahren dafür
CN110730785B (zh) 一种脂肪酸胆汁酸偶合物的晶型及其制备方法和用途
JP2008540449A (ja) （２ｅ，４ｓ）−４−［（ｎ−｛［（２ｒ）−１−イソプロピルピペリジン−２−イル］−カルボニル｝−３−メチル−ｌ−バリル）（メチル）アミノ］−２，５−ジメチルヘキサ−２−エン酸の非溶媒和およびホストゲスト溶媒和結晶フォーム、およびそれらの医薬的使用
WO2014024210A2 (en) Novel polymorphs of doxercalciferol

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131031

FZDE Dead

Effective date: 20160504